Postembryonic development of pycnogonids: A deeper look inside

Sea spiders form a small, enigmatic group of recent chelicerates, with an unusual bodyplan, oligosegmented larvae and a postembryonic development that is punctuated by many moults. To date, only a few papers examined the anatomical and ultrastructural modifications of the larvae and various instars. Here we traced both internal and external events of the whole postembryonic development in Nymphon brevirostre HODGE 1863 using histology, SEM, TEM and confocal microscopy. During postembryonic development, larvae of this species undergo massive reorganization: spinning apparatus and chelar glands disappear; larval legs redifferentiate; three new segments and the abdomen are formed with their corresponding internal organs and appendages; circulatory and reproductive systems develop anew and the digestive and the nervous systems change dramatically. The body cavity remains schizocoelic throughout development, and no traces of even transitory coeloms were found in any instar. In Nymphon brevirostre, just like in Artemia salina LINNAEUS 1758 the heart arises through differentiation of the already existing schizocoel, and thus the circulatory systems of arthropods and annelids are not homologous. We found that classical chelicerate tagmata, prosoma and opisthosoma, are inapplicable to adult pycnogonids, with the most striking difference being the fate and structure of the seventh appendage-bearing segment.     

A look inside odorant-binding proteins in insect chemoreception

Detection of chemical signals from the environment through olfaction is an indispensable mechanism for maintaining an insect’s life, evoking critical behavioral responses. Among several proteins involved in the olfactory perception process, the odorant binding protein (OBP) has been shown to be essential for a normally functioning olfactory system. This paper discusses the role of OBPs in insect chemoreception. Here, structural aspects, mechanisms of action and binding affinity of such proteins are reviewed, as well as their promising application as molecular targets for the development of new strategies for insect population management and other technological purposes.     

Iron trafficking inside the brain

Iron, an essential element for all cells of the body, including those of the brain, is transported bound to transferrin in the blood and the general extracellular fluid of the body. The demonstration of transferrin receptors on brain capillary endothelial cells (BCECs) more than 20 years ago provided the evidence for the now accepted view that the first step in blood to brain transport of iron is receptor-mediated endocytosis of transferrin. Subsequent steps are less clear. However, recent investigations which form the basis of this review have shed some light on them and also indicate possible fruitful avenues for future research. They provide new evidence on how iron is released from transferrin on the abluminal surface of BCECs, including the role of astrocytes in this process, how iron is transported in brain extracellular fluid, and how iron is taken up by neurons and glial cells. We propose that the divalent metal transporter 1 is not involved in iron transport through the BCECs. Instead, iron is probably released from transferrin on the abluminal surface of these cells by the action of citrate and ATP that are released by astrocytes, which form a very close relationship with BCECs. Complexes of iron with citrate and ATP can then circulate in brain extracellular fluid and may be taken up in these low-molecular weight forms by all types of brain cells or be bound by transferrin and taken up by cells which express transferrin receptors. Some iron most likely also circulates bound to transferrin, as neurons contain both transferrin receptors and divalent metal transporter 1 and can take up transferrin-bound iron. The most likely source for transferrin in the brain interstitium derives from diffusion from the ventricles. Neurons express the iron exporting carrier, ferroportin, which probably allows them to excrete unneeded iron. Astrocytes lack transferrin receptors. Their source of iron is probably that released from transferrin on the abluminal surface of BCECs. They probably to export iron by a mechanism involving a membrane-bound form of the ferroxidase, ceruloplasmin. Oligodendrocytes also lack transferrin receptors. They probably take up non-transferrin bound iron that gets incorporated in newly synthesized transferrin, which may play an important role for intracellular iron transport.     

Action of estrogens in the aging brain: Dementia and cognitive aging

Background

Menopause is associated with sharp declines in concentrations of circulating estrogens. This change in hormone milieu has the potential to affect brain functions relevant to dementia and cognitive aging.

Scope of review

Focused review of published results of randomized clinical trials of estrogen-containing hormone therapy for Alzheimer's disease treatment and dementia prevention, observational research on cognition across the menopause transition, and observational research on the association of hormone therapy and Alzheimer's disease risk.

Major conclusions

Clinical trial evidence supports conclusions that estrogen therapy does not improve dementia symptoms in women with Alzheimer's disease and that estrogen-containing hormone therapy initiated after about age 65 years increases dementia risk. Hormone therapy begun in this older postmenopausal group does not ameliorate cognitive aging. Cognitive outcomes of midlife hormone exposures are less well studied. There is no strong indication of short-term cognitive benefit of hormone use after natural menopause, but clinical trial data are sparse. Little research addresses midlife estrogen use after surgical menopause; limited clinical trial data imply short-term benefit of prompt initiation at the time of oophorectomy. Whether exogenous estrogen exposures in the early postmenopause affect Alzheimer risk or cognitive aging much later in life is unanswered by available data. Observational results raise the possibility of long-term cognitive benefit, but bias is a concern in interpreting these findings.

General significance

Estrogen-containing hormone therapy should not be initiated after age 65 to prevent dementia or remediate cognitive aging. Further research is needed to understand short-term and long-term cognitive effects of estrogen exposures closer to the age of menopause.     

Zinc and the aging brain

Alterations in trace element homeostasis could be involved in the pathology of dementia, and in particular of Alzheimer’s disease (AD). Zinc is a structural or functional component of many proteins, being involved in numerous and relevant physiological functions. Zinc homeostasis is affected in the elderly, and current evidence points to alterations in the cellular and systemic distribution of zinc in AD. Although the association of zinc and other metals with AD pathology remains unclear, therapeutic approaches designed to restore trace element homeostasis are being tested in clinical trials. Not only could zinc supplementation potentially benefit individuals with AD, but zinc supplementation also improves glycemic control in the elderly suffering from diabetes mellitus. However, the findings that select genetic polymorphisms may alter an individual’s zinc intake requirements should be taken into consideration when planning zinc supplementation. This review will focus on current knowledge regarding pathological and protective mechanisms involving brain zinc in AD to highlight areas where future research may enable development of new and improved therapies.     

Reactive oxygen species and protein oxidation in aging: a look back, a look ahead.

The existence of free radicals, as chemical entities, was inferred 100 years ago but not universally accepted for some 30-40 years. The existence and importance of free radicals in biological systems was not recognized until the mid 1950s, by a small number of visionary scientists who can be credited with founding the field of reactive oxygen biochemistry. For most of the remaining 20th century, reactive oxygen species (ROS) were considered a type of biochemical "rusting agent" that caused stochastic tissue damage and disease. As we enter the 21st century, reactive oxygen biochemistry is maturing as a discipline and establishing its importance among the biomedical sciences. It is now recognized that virtually every disease state involves some degree of oxidative stress. Moreover, we are now beginning to recognize that ROS are produced in a well-regulated manner to help maintain homeostasis on the cellular level in normal, healthy tissue. This review summarizes the history of reactive oxygen biochemistry, outlining major paradigm shifts that the field has undergone and continues to experience. The contributions of Earl Stadtman to the recent history of the field (1980-present) are especially highlighted. The role of ROS in signal transduction is presented in some detail as central to the latest paradigm shift. Emerging technologies, particularly proteomic technologies, are discussed that will facilitate further evolution in the field of reactive oxygen biochemistry.     

DNA damage and repair in brain: relationship to aging.

The usefulness of conducting DNA damage and repair studies in a postmitotic tissue like brain is emphasized. We review studies that use brain as a tissue to test the validity of the DNA damage and repair hypothesis of aging. As far as the accumulation of age dependent DNA damage is concerned, the data appear to overwhelmingly support the hypothesis. However, attempts to demonstrate a decline in DNA repair capacity as a function of age are conflicting and equally divided. Possible reasons for this discrepancy are discussed. It is suggested that assessment of the repair capacity of neurons with respect to a specific type of damage in a specific gene might yield more definitive answers regarding the role of DNA repair potential in the aging process and as a longevity assurance system.     

Mechanisms of diabetes-induced impairements of serotonin release from rat brain synaptosomes: effect of nicotinamide

It has been previously shown that diabetes-associated central nervous system abnormalities are characterized by progressive alterations of neurotransmission. In particular, recent studies from our group have demonstrated that more early diabetes is accompanied by the increased spontaneous serotonin release from isolated synaptic endings; however the mechanism is still not clear. The current study was undertaken to estimate the relative importance of membrane potential and extracellular Ca2+ in the serotonin secretion process in diabetes. With the premise that increased phosphorylation of target proteins may be responsible for the increase in transmitter release we tested whether cAMP/PKA-mediated phosphorylations as well as mono-ADP-ribosylation of effector proteins were implicated in diabetes-associated brain failures. In addition, the effects of nicotinamide, a multiple-action compound, were examined. It was shown that diabetes caused a significant increase in spontaneous release of [2-(14)C]serotonin that was accompanied by synaptic membranes depolarization. Omission of Ca2+ from the incubation medium largely inhibited serotonin release only in untreated diabetes. Exposure of diabetic synaptosomes to cAMP-dependent protein kinase inhibitor H89, similar to Ca2+ -free medium, downregulated serotonin release. The level of constitutively mono-ADP-ribosylated proteins of diabetic synaptosomes was elevated vs control. Protein mono-ADP-ribosylation induced by cholera toxin (CTX), activator of Gs-protein-coupled adenylyl cyclase, resulted in excessive 1.2-fold enhancement over basal level but to the less extent in diabetes as compared with that of control. Nevertheless, CTX as well as forskolin exerted more strong stimulating effect on serotonin release from diabetic synaptosomes as compared to control. H89 counteracted CTX-related action on this variable strongly suggesting that impaired serotonin release is, at least, dependent on Gs-protein-mediated phosphorylation. Nicotinamide treatment virtually normalized both protein mono-ADP-ribosylation and serotonin release as well as synaptosomal response to all stimuli used. The data suggest that alterations in protein mono-ADP-ribosylation may be involved as a possible mechanism responsible for the impaired neurotransmission in diabetes and nicotinamide may efficiently protect against ADP-ribosylationmediated abnormalities in brain function.